Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia Orum ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
Orum Therapeutics Inc. on April 26 pulled the plug on a U.S.-based phase I study of ORM-5029, its lead oncology degrader antibody conjugate (DAC) asset, a decision that came months after the company ...
She shares how Orm in real life compares to Orm in the movie, takes us behind the scenes with fun stories, and lets her charming personality shine throughout the interview.
ABSTRACT: Microservices have revolutionized traditional software architecture. While monolithic designs continue to be common, particularly in legacy applications, there is a growing trend towards the ...
Imagine this: You’re a writer working on a script or—better yet—you’ve just finished your latest draft. You’ve spent months crafting characters, structuring plot, and developing story. You put the ...
The sample application that showcases the different capabilities of the Quarkus Platform. The application poles every hour twitter for twitter trend in particular place, stores results in-memory h2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results